To develop and evaluate a novel chitosan-coated submicron emulsion (SubE) incorporating a ciprofloxacin-potassium sorbate (CIF-PoS) ionic complex for improved ocular drug delivery, addressing limitations of conventional eye drops such as poor corneal retention and bioavailability.
Methods
The CIF-PoS complex was prepared via ion-pairing at optimized molar ratios and pH, characterized by ¹H NMR. SubEs were formulated using high-energy emulsification with egg lecithin, Pluronic F-68®, and chitosan. Physicochemical properties (droplet size, zeta potential, viscosity, encapsulation efficiency) were assessed. In vitro release was studied via dialysis. Ex vivo antimicrobial efficacy against Pseudomonas aeruginosa biofilms was evaluated using MIC/MBC assays. In vivo corneal retention was examined in Wistar rats using fluorescence microscopy and HPLC-MS for pharmacokinetics. Stability was tested per ICH guidelines.
Results
The optimized SubE-CN-CIF-PoS exhibited a droplet size of 227.1 ± 5.6 nm and a polydispersity index (PdI) of 0.24 ± 0.03, + 33.2 mV zeta potential, 91.43% encapsulation efficiency, and sustained release (78% over 24 h). It showed comparable MIC (0.0051 µg/mL) and MBC (0.0114 µg/mL) compared to marketed CIF formulations (MF). In vivo, it maintained therapeutic corneal levels for 12 h (20.9% higher than controls). Stability was robust over 6 months.
Conclusion
This biomimetic system enhances corneal adhesion, penetration, and antibacterial action, offering potential for reduced dosing frequency and improved outcomes in ocular infections. No trial registration required as this is preclinical research.
{"title":"Chitosan-Modified Submicron Emulsions for Enhanced Ocular Delivery and Antibacterial Efficacy of Ciprofloxacin","authors":"Durga Pandey, Preeti Singh, Girijesh Kumar Pandey, Alok Kumar Mahor, Prashant Pandey","doi":"10.1007/s12247-025-10334-8","DOIUrl":"10.1007/s12247-025-10334-8","url":null,"abstract":"<div><h3>Purpose</h3><p>To develop and evaluate a novel chitosan-coated submicron emulsion (SubE) incorporating a ciprofloxacin-potassium sorbate (CIF-PoS) ionic complex for improved ocular drug delivery, addressing limitations of conventional eye drops such as poor corneal retention and bioavailability.</p><h3>Methods</h3><p>The CIF-PoS complex was prepared via ion-pairing at optimized molar ratios and pH, characterized by ¹H NMR. SubEs were formulated using high-energy emulsification with egg lecithin, Pluronic F-68<sup>®</sup>, and chitosan. Physicochemical properties (droplet size, zeta potential, viscosity, encapsulation efficiency) were assessed. In vitro release was studied via dialysis. Ex vivo antimicrobial efficacy against <i>Pseudomonas aeruginosa</i> biofilms was evaluated using MIC/MBC assays. In vivo corneal retention was examined in Wistar rats using fluorescence microscopy and HPLC-MS for pharmacokinetics. Stability was tested per ICH guidelines.</p><h3>Results</h3><p>The optimized SubE-CN-CIF-PoS exhibited a droplet size of 227.1 ± 5.6 nm and a polydispersity index (PdI) of 0.24 ± 0.03, + 33.2 mV zeta potential, 91.43% encapsulation efficiency, and sustained release (78% over 24 h). It showed comparable MIC (0.0051 µg/mL) and MBC (0.0114 µg/mL) compared to marketed CIF formulations (MF). In vivo, it maintained therapeutic corneal levels for 12 h (20.9% higher than controls). Stability was robust over 6 months.</p><h3>Conclusion</h3><p>This biomimetic system enhances corneal adhesion, penetration, and antibacterial action, offering potential for reduced dosing frequency and improved outcomes in ocular infections. No trial registration required as this is preclinical research.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"21 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145982508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Imidazo[1,2-a]pyridine is a pivotal fused heterocycle in medicinal chemistry, widely recognized as a foundational scaffold due to its diverse biological and therapeutic applications. The need for efficient, sustainable, and high-yielding synthetic methodologies for imidazo[1,2-a]pyridine derivatives continue to drive research interest in this domain.
Methods
The present study focuses on developing a highly efficient and sustainable synthetic strategy for imidazo[1,2-a]pyridine derivatives with improved yield and broad applicability. A multistep reaction pathway was employed using readily available starting materials, followed by structural confirmation of the synthesized compounds through FTIR, ¹H NMR, ¹³C NMR, and mass spectrometry analyses.
Results
The optimized reaction conditions yielded products in excellent yields ranging from 91% to 98%, demonstrating superior efficiency, enhanced purity, and high scalability compared to conventional methods. Furthermore, molecular docking studies were performed to evaluate the binding affinity of the synthesized derivatives toward the target protein, revealing significant interactions with key active-site residues that support their potential biological relevance. Drug-likeness assessment based on Lipinski’s Rule of Five confirmed that all compounds exhibited acceptable physicochemical properties, indicating good oral bioavailability and favorable pharmacokinetic profiles. In this approach, alternative coupling systems such as DMTMM and greener solvents (MeCN, 2-MeTHF) are also discussed for further improving the sustainability profile.
Conclusion
Overall, this novel synthetic approach provides a reliable, eco-efficient, and versatile route for the formation of imidazo[1,2-a]pyridine frameworks and holds strong potential for future applications in medicinal chemistry and pharmaceutical development.
咪唑[1,2-a]吡啶是药物化学中重要的融合杂环,因其广泛的生物和治疗用途而被广泛认为是基础支架。对咪唑[1,2-a]吡啶衍生物的高效、可持续和高产合成方法的需求继续推动着这一领域的研究兴趣。方法研究一种高效、可持续的咪唑[1,2-a]吡啶衍生物的合成策略,该策略可提高收率并具有广泛的适用性。采用多步反应途径,使用现成的原料,然后通过FTIR,¹H NMR,¹³C NMR和质谱分析对合成的化合物进行结构确认。结果优化后的反应条件与常规方法相比,收率为91% ~ 98%,效率高,纯度高,可扩展性好。此外,进行分子对接研究以评估合成的衍生物与目标蛋白的结合亲和力,揭示了与关键活性位点残基的显著相互作用,支持其潜在的生物学相关性。基于Lipinski 's Rule of Five的药物相似性评估证实,所有化合物都具有可接受的物理化学性质,表明良好的口服生物利用度和良好的药代动力学特征。在这种方法中,还讨论了DMTMM和绿色溶剂(MeCN, 2-MeTHF)等替代耦合系统,以进一步提高可持续性。综上所述,该方法为咪唑[1,2-a]吡啶框架的合成提供了一条可靠、环保、多功能的合成途径,在药物化学和药物开发方面具有很大的应用潜力。
{"title":"Efficient and Scalable Synthesis of Imidazo[1,2-a]pyridine-8-Carboxamides: a Versatile Methodology","authors":"Drashti Shah, Bhargav Bhimani, Ranjitsinh Dabhi, Vidhi Trivedi, Rohit Bhatia, Divy Patel, Kunal Nepali, Ashish Patel","doi":"10.1007/s12247-025-10325-9","DOIUrl":"10.1007/s12247-025-10325-9","url":null,"abstract":"<div><h3>Purpose</h3><p>Imidazo[1,2-<i>a</i>]pyridine is a pivotal fused heterocycle in medicinal chemistry, widely recognized as a foundational scaffold due to its diverse biological and therapeutic applications. The need for efficient, sustainable, and high-yielding synthetic methodologies for imidazo[1,2-<i>a</i>]pyridine derivatives continue to drive research interest in this domain.</p><h3>Methods</h3><p>The present study focuses on developing a highly efficient and sustainable synthetic strategy for imidazo[1,2-<i>a</i>]pyridine derivatives with improved yield and broad applicability. A multistep reaction pathway was employed using readily available starting materials, followed by structural confirmation of the synthesized compounds through FTIR, ¹H NMR, ¹³C NMR, and mass spectrometry analyses.</p><h3>Results</h3><p>The optimized reaction conditions yielded products in excellent yields ranging from 91% to 98%, demonstrating superior efficiency, enhanced purity, and high scalability compared to conventional methods. Furthermore, molecular docking studies were performed to evaluate the binding affinity of the synthesized derivatives toward the target protein, revealing significant interactions with key active-site residues that support their potential biological relevance. Drug-likeness assessment based on Lipinski’s Rule of Five confirmed that all compounds exhibited acceptable physicochemical properties, indicating good oral bioavailability and favorable pharmacokinetic profiles. In this approach, alternative coupling systems such as DMTMM and greener solvents (MeCN, 2-MeTHF) are also discussed for further improving the sustainability profile.</p><h3>Conclusion</h3><p>Overall, this novel synthetic approach provides a reliable, eco-efficient, and versatile route for the formation of imidazo[1,2-<i>a</i>]pyridine frameworks and holds strong potential for future applications in medicinal chemistry and pharmaceutical development.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"21 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145982724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13DOI: 10.1007/s12247-025-10358-0
Ranjit K. Harwansh, Rohitas Deshmukh, Mohammad Akhlaquer Rahman, Rajendra K. Jangde
Purpose
This study aimed to use response surface methods to create and optimize a ferulic acid (FA)-transferosome (FATF)-based gel (FATF-G). The goal of the study was to create FATF-G in order to get improved photoprotection against UVA radiation.
Methods
FATF was prepared by the thin-film hydration technique and optimized by response surface methodology (RSM). Optimized FATF composed of 20 mg (phospholipid, soy lecithin, SL), Tween 80 (5 mL), and sonication duration (20 min) with solvent chloroform and methanol (2:1, v/v). Entrapment efficiency (%EE), ex vivo skin permeability, solubility, TEM, FTIR, UV, Zetasizer, and stability tests were used to characterize FATF. FATF-G, FACG, and FAPL-G were checked for their photoprotective efficacy and membrane permeability in a rat model.
Results
FATF produced the highest %EE of 99.48 ± 0.54%. Compared to FACG, FATF-G has demonstrated a considerably stronger photoprotection effect (***P < 0.01), superior permeability (92.08 ± 0.86%), and longer release over 24 h. The FATF-G’s improved drug absorption through skin is possible because FATF had a better permeation coefficient [Kp 4.73 ± 0.07 (cm/h)] and greater solubility (8137.12 ± 1.10 µg/mL) as compared to others. Skin antioxidant defense systems such as GPX, GRD, CAT, MDA, GSH, SOD, and carbonyl protein were significantly elevated by FATF-G (***P < 0.01) against UVA.
Conclusion
FATF-G, the optimized gel formulation, considerably outperformed FACG in terms of skin permeability and photoprotection activity (***P < 0.01). Thus, this novel gel system of FA may have the potential for topical delivery to get enhanced therapeutic efficacy and photoprotection against harmful ultraviolet lights.
{"title":"Optimization of Ferulic Acid-Loaded Transferosomal Gel Using Box-Behnken Design: A Novel Approach for Enhanced Photoprotection","authors":"Ranjit K. Harwansh, Rohitas Deshmukh, Mohammad Akhlaquer Rahman, Rajendra K. Jangde","doi":"10.1007/s12247-025-10358-0","DOIUrl":"10.1007/s12247-025-10358-0","url":null,"abstract":"<div><h3>Purpose</h3><p>This study aimed to use response surface methods to create and optimize a ferulic acid (FA)-transferosome (FATF)-based gel (FATF-G). The goal of the study was to create FATF-G in order to get improved photoprotection against UVA radiation.</p><h3>Methods</h3><p>FATF was prepared by the thin-film hydration technique and optimized by response surface methodology (RSM). Optimized FATF composed of 20 mg (phospholipid, soy lecithin, SL), Tween 80 (5 mL), and sonication duration (20 min) with solvent chloroform and methanol (2:1, v/v). Entrapment efficiency (%EE), ex vivo skin permeability, solubility, TEM, FTIR, UV, Zetasizer, and stability tests were used to characterize FATF. FATF-G, FACG, and FAPL-G were checked for their photoprotective efficacy and membrane permeability in a rat model.</p><h3>Results</h3><p>FATF produced the highest %EE of 99.48 ± 0.54%. Compared to FACG, FATF-G has demonstrated a considerably stronger photoprotection effect (<sup>***</sup><i>P</i> < 0.01), superior permeability (92.08 ± 0.86%), and longer release over 24 h. The FATF-G’s improved drug absorption through skin is possible because FATF had a better permeation coefficient [Kp 4.73 ± 0.07 (cm/h)] and greater solubility (8137.12 ± 1.10 µg/mL) as compared to others. Skin antioxidant defense systems such as GPX, GRD, CAT, MDA, GSH, SOD, and carbonyl protein were significantly elevated by FATF-G (<sup>***</sup><i>P</i> < 0.01) against UVA.</p><h3>Conclusion</h3><p>FATF-G, the optimized gel formulation, considerably outperformed FACG in terms of skin permeability and photoprotection activity (<sup>***</sup><i>P</i> < 0.01). Thus, this novel gel system of FA may have the potential for topical delivery to get enhanced therapeutic efficacy and photoprotection against harmful ultraviolet lights.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"21 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145982723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1007/s12247-025-10353-5
Miah Roney, Md. Nazim Uddin, Mohd Fadhlizil Fasihi Mohd Aluwi, Hadiza Shehu Giwa, Jianbo Xiao, Hazrulrizawati Abd Hamid
Breast cancer remains one of the most prevalent malignancies among women worldwide, underscoring the urgent need for safer and more effective therapeutic agents. This study investigates the potential anti-breast cancer properties of bioactive compounds derived from Polyalthia bullata King using an integrative computational and experimental approach. Sequential solvent extraction with solvents of varying polarities was employed to maximize the diversity of phytochemicals extracted from P. bullata. The major bioactive constituents were identified through ultra-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry (UPLC-QTOF/MS) analysis. The identified 130 compounds underwent ADMET-based screening to predict their drug-likeness and pharmacokinetic profiles. Drug-like 8 compounds were further explored through network pharmacology to predict potential breast cancer-related targets and involved signaling pathways. From this, 30,453 breast cancer-associated targets were retrieved from the GeneCards database, and 1,619 compound-related targets were identified via SwissTargetPrediction and SuperPred. Protein-protein interaction (PPI) network analysis revealed 646 overlapping targets. Subsequent Gene Ontology (GO) and KEGG pathway enrichment analyses highlighted the hsa05200: Pathways in cancer as a central mechanism, involving key proteins such as AKT1, GAPDH, and IL6. Molecular docking studies identified myricetin, bowdichione, and 4-methyl-1 H-benzo[g]quinoline-2,5,10-trione as top candidates with strong binding affinities toward AKT1. These findings were further validated through molecular dynamics (MD) simulations, principal component analysis (PCA), free energy landscape (FEL) analysis, and Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) calculations, all of which confirmed the stability and favorable binding of the compounds to the target protein. Overall, this study suggests that P. bullata-derived compounds, particularly myricetin, bowdichione, and 4-methyl-1 H-benzo[g]quinoline-2,5,10-trione, hold promise as potential therapeutic agents against breast cancer and warrant further experimental investigation.
乳腺癌仍然是全世界妇女中最常见的恶性肿瘤之一,强调迫切需要更安全、更有效的治疗药物。本研究采用综合计算和实验的方法研究了从牛耳草中提取的生物活性化合物的潜在抗乳腺癌特性。采用不同极性溶剂序贯萃取法,最大限度地提高了黄顶草植物化学成分的多样性。通过超高效液相色谱-四极杆/飞行时间质谱(UPLC-QTOF/MS)分析鉴定其主要生物活性成分。鉴定出的130种化合物进行了基于admet的筛选,以预测它们的药物相似性和药代动力学特征。通过网络药理学进一步探索8种药物样化合物,预测潜在的乳腺癌相关靶点及相关信号通路。由此,从GeneCards数据库中检索到30,453个乳腺癌相关靶点,并通过SwissTargetPrediction和SuperPred确定了1,619个化合物相关靶点。蛋白-蛋白相互作用(PPI)网络分析发现646个重叠靶点。随后的基因本体(GO)和KEGG通路富集分析强调了hsa05200通路在癌症中的核心机制,涉及AKT1、GAPDH和IL6等关键蛋白。分子对接研究发现杨梅素、鲍地酮和4-甲基-1 h -苯并[g]喹啉-2,5,10-三酮是与AKT1具有强结合亲和力的首选候选药物。通过分子动力学(MD)模拟、主成分分析(PCA)、自由能景观(FEL)分析和分子力学/泊松-玻尔兹曼表面积(MM/PBSA)计算进一步验证了这些发现,所有这些结果都证实了化合物与目标蛋白的稳定性和良好的结合。总的来说,这项研究表明,布拉塔属植物衍生的化合物,特别是杨梅素、鲍地酮和4-甲基-1 h -苯并喹啉-2,5,10-三酮,有望成为治疗乳腺癌的潜在药物,值得进一步的实验研究。
{"title":"Targeting Breast Cancer with Polyalthia bullata Compounds: Insights from ADMET, Network Pharmacology, and Molecular Modeling","authors":"Miah Roney, Md. Nazim Uddin, Mohd Fadhlizil Fasihi Mohd Aluwi, Hadiza Shehu Giwa, Jianbo Xiao, Hazrulrizawati Abd Hamid","doi":"10.1007/s12247-025-10353-5","DOIUrl":"10.1007/s12247-025-10353-5","url":null,"abstract":"<div><p>Breast cancer remains one of the most prevalent malignancies among women worldwide, underscoring the urgent need for safer and more effective therapeutic agents. This study investigates the potential anti-breast cancer properties of bioactive compounds derived from <i>Polyalthia bullata</i> King using an integrative computational and experimental approach. Sequential solvent extraction with solvents of varying polarities was employed to maximize the diversity of phytochemicals extracted from <i>P. bullata</i>. The major bioactive constituents were identified through ultra-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry (UPLC-QTOF/MS) analysis. The identified 130 compounds underwent ADMET-based screening to predict their drug-likeness and pharmacokinetic profiles. Drug-like 8 compounds were further explored through network pharmacology to predict potential breast cancer-related targets and involved signaling pathways. From this, 30,453 breast cancer-associated targets were retrieved from the GeneCards database, and 1,619 compound-related targets were identified via SwissTargetPrediction and SuperPred. Protein-protein interaction (PPI) network analysis revealed 646 overlapping targets. Subsequent Gene Ontology (GO) and KEGG pathway enrichment analyses highlighted the hsa05200: Pathways in cancer as a central mechanism, involving key proteins such as AKT1, GAPDH, and IL6. Molecular docking studies identified myricetin, bowdichione, and 4-methyl-1 H-benzo[g]quinoline-2,5,10-trione as top candidates with strong binding affinities toward AKT1. These findings were further validated through molecular dynamics (MD) simulations, principal component analysis (PCA), free energy landscape (FEL) analysis, and Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) calculations, all of which confirmed the stability and favorable binding of the compounds to the target protein. Overall, this study suggests that <i>P. bullata</i>-derived compounds, particularly myricetin, bowdichione, and 4-methyl-1 H-benzo[g]quinoline-2,5,10-trione, hold promise as potential therapeutic agents against breast cancer and warrant further experimental investigation.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"21 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12247-025-10353-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145982939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1007/s12247-025-10320-0
Omaish S. Alqahtani, Uday M. Muddapur, Tisha Kawad, Aparna Shenvi, Bassam S. M. Al Kazman, Mohammed A. Alshamrani, Ibrahim Ahmed Shaikh, Ibrahim Aljaezi, Adel Aljadaan, Aejaz Abdullatif Khan, Basheerahmed Abdulaziz Mannasaheb, Sunil S. More
Aloe vera (L.) Burm.f. (A. vera) is widely recognized for its medicinal properties, yet the therapeutic potential of its flowers remains underexplored. This study investigates the phytochemical compounds and pharmacological relevance of A. vera flowers to identify novel plant-based therapeutic agents. Phytochemical exploration studies of A.vera were done by subjecting it to Soxhlet extraction process and phytochemical screening was carried out using 18 tests which detected various constituents like alkaloids, flavanoids, terpenoids, saponins, tannins, glycosides, anthraquinones, diterpenes. Zonal inhibition activity of A.vera flower extract showed a very strong antimicrobial activity against Listeria monocytogenes, Salmonella typhi, Escherichia coli, Bacillus subtilis, Staphylococcus aureus. LC-MS was carried out to identify the bioactive compounds present in flower extract. Toxicity and carcinogenicity was confirmed by ADMET profile and screened on the basis of acceptance of Lipinsky, Pfizer, GSK. Golden triangle, Ghose, Veber, Egan, Muegge, QED & NP score. Four phytochemical compounds were shortlisted out of 8 based on the ADMET profile which were subjected to Molecular Docking with the Protein PDB id:108A coupled with Human ACE. Among these, tschimganin demonstrated strong binding energy affinity score (-9.5 kcal/mol) and was subjected to Molecular Dynamic simulation, which confirmed the stability of the compound supporting its potential as a lead compound. These findings highlight A. vera flowers as a promising source of bioactive compounds with therapeutic potential. Tschimganin shows strong molecular interaction and stability, suggesting its viability for the development of pharmaceuticals. Other compounds such as seneciphyllin (-9.2 kcal/mol) and cianidanol (-8.7 kcal/mol) were found to be effective as they exhibited several therapeutic applications, including antioxidant, anti-inflammatory, neuroprotective, anticancer, and neural toxicity prevention properties. These phytochemical bioactive compounds present in A.vera flower such as Tschimganin, 8-Hydroxy-13,14,15,16-tetranor-12-labdanoic acid, seneciphyllin, cianidanol, are neither present in A. vera leaf nor gel, so this significant/novel finding of the compounds reported paves the way as promising bioactive agents for therapeutic purposes.
{"title":"Integrated Phytochemical Exploration Studies and Computational Biology Approaches of Aloe Vera (L.) Burm.f., Flowers Coupled with Human ACE","authors":"Omaish S. Alqahtani, Uday M. Muddapur, Tisha Kawad, Aparna Shenvi, Bassam S. M. Al Kazman, Mohammed A. Alshamrani, Ibrahim Ahmed Shaikh, Ibrahim Aljaezi, Adel Aljadaan, Aejaz Abdullatif Khan, Basheerahmed Abdulaziz Mannasaheb, Sunil S. More","doi":"10.1007/s12247-025-10320-0","DOIUrl":"10.1007/s12247-025-10320-0","url":null,"abstract":"<div><p><i>Aloe vera (L.)</i> Burm.f. <i>(A. vera)</i> is widely recognized for its medicinal properties, yet the therapeutic potential of its flowers remains underexplored. This study investigates the phytochemical compounds and pharmacological relevance of <i>A. vera</i> flowers to identify novel plant-based therapeutic agents. Phytochemical exploration studies of <i>A.vera</i> were done by subjecting it to Soxhlet extraction process and phytochemical screening was carried out using 18 tests which detected various constituents like alkaloids, flavanoids, terpenoids, saponins, tannins, glycosides, anthraquinones, diterpenes. Zonal inhibition activity of <i>A.vera</i> flower extract showed a very strong antimicrobial activity against <i>Listeria monocytogenes</i>,<i> Salmonella typhi</i>,<i> Escherichia coli</i>,<i> Bacillus subtilis</i>,<i> Staphylococcus aureus. </i>LC-MS was carried out to identify the bioactive compounds present in flower extract. Toxicity and carcinogenicity was confirmed by ADMET profile and screened on the basis of acceptance of Lipinsky, Pfizer, GSK. Golden triangle, Ghose, Veber, Egan, Muegge, QED & NP score. Four phytochemical compounds were shortlisted out of 8 based on the ADMET profile which were subjected to Molecular Docking with the Protein PDB id:108A coupled with Human ACE. Among these, tschimganin demonstrated strong binding energy affinity score (-9.5 kcal/mol) and was subjected to Molecular Dynamic simulation, which confirmed the stability of the compound supporting its potential as a lead compound. These findings highlight <i>A. vera</i> flowers as a promising source of bioactive compounds with therapeutic potential. Tschimganin shows strong molecular interaction and stability, suggesting its viability for the development of pharmaceuticals. Other compounds such as seneciphyllin (-9.2 kcal/mol) and cianidanol (-8.7 kcal/mol) were found to be effective as they exhibited several therapeutic applications, including antioxidant, anti-inflammatory, neuroprotective, anticancer, and neural toxicity prevention properties. These phytochemical bioactive compounds present in <i>A.vera</i> flower such as Tschimganin, 8-Hydroxy-13,14,15,16-tetranor-12-labdanoic acid, seneciphyllin, cianidanol, are neither present in <i>A. vera</i> leaf nor gel, so this significant/novel finding of the compounds reported paves the way as promising bioactive agents for therapeutic purposes.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"21 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145982769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1007/s12247-025-10293-0
Murine Sharmili S, Yesubai Rubavathy C
Purpose
The primary purpose of this study is to investigate whether low-cost thermal imaging, combined with optimized deep learning techniques, can provide an accurate, safe, and non-invasive solution for the automated diagnosis and therapeutic monitoring of respiratory diseases. Specifically, the research addresses the question of whether thermal patterns associated with lung inflammation can be effectively learned and discriminated to reliably classify COVID-19, pneumonia, and healthy cases, while maintaining high diagnostic accuracy and model interpretability suitable for resource-limited clinical settings.
Methods
A thermal imaging–driven diagnostic framework was designed incorporating robust image preprocessing, multi-domain handcrafted feature extraction, and a hybrid feature selection strategy that combines the Coati Optimization Algorithm and the Marine Predators Algorithm. Customized deep learning models, including multilayer perceptron (MLP), recurrent neural network (RNN), attention-based convolutional neural network (CNN), and transfer learning–based architectures, were trained and evaluated using simulated thermal images representing COVID-19, pneumonia, and healthy conditions. Model interpretability was enhanced using Gradient-weighted Class Activation Mapping (Grad-CAM).
Results
The optimized framework achieved high classification performance, with accuracies of 98.58% using a 70/30 train–test split and 99.57% using an 80/20 split. Grad-CAM visualizations consistently identified disease-relevant thermal regions that contributed to model predictions, supporting both diagnostic reliability and interpretability.Conclusion:The proposed low-cost thermal imaging and deep learning framework demonstrates strong potential as an accessible, radiation-free solution for automated screening and monitoring of respiratory diseases. The high diagnostic accuracy and interpretability indicate its suitability for large-scale, resource-constrained healthcare settings.
{"title":"Therapeutic Monitoring and Non-Invasive Diagnosis of Lung Disease (Pneumonia and COVID-19) Using Low-Cost Thermal Imaging and DEEP Learning","authors":"Murine Sharmili S, Yesubai Rubavathy C","doi":"10.1007/s12247-025-10293-0","DOIUrl":"10.1007/s12247-025-10293-0","url":null,"abstract":"<div><h3>Purpose</h3><p>The primary purpose of this study is to investigate whether low-cost thermal imaging, combined with optimized deep learning techniques, can provide an accurate, safe, and non-invasive solution for the automated diagnosis and therapeutic monitoring of respiratory diseases. Specifically, the research addresses the question of whether thermal patterns associated with lung inflammation can be effectively learned and discriminated to reliably classify COVID-19, pneumonia, and healthy cases, while maintaining high diagnostic accuracy and model interpretability suitable for resource-limited clinical settings.</p><h3>Methods</h3><p>A thermal imaging–driven diagnostic framework was designed incorporating robust image preprocessing, multi-domain handcrafted feature extraction, and a hybrid feature selection strategy that combines the Coati Optimization Algorithm and the Marine Predators Algorithm. Customized deep learning models, including multilayer perceptron (MLP), recurrent neural network (RNN), attention-based convolutional neural network (CNN), and transfer learning–based architectures, were trained and evaluated using simulated thermal images representing COVID-19, pneumonia, and healthy conditions. Model interpretability was enhanced using Gradient-weighted Class Activation Mapping (Grad-CAM).</p><h3>Results</h3><p>The optimized framework achieved high classification performance, with accuracies of 98.58% using a 70/30 train–test split and 99.57% using an 80/20 split. Grad-CAM visualizations consistently identified disease-relevant thermal regions that contributed to model predictions, supporting both diagnostic reliability and interpretability.Conclusion:The proposed low-cost thermal imaging and deep learning framework demonstrates strong potential as an accessible, radiation-free solution for automated screening and monitoring of respiratory diseases. The high diagnostic accuracy and interpretability indicate its suitability for large-scale, resource-constrained healthcare settings.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"21 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145982767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Miconazole nitrate, a BCS Class II drug (< 3 µg/mL solubility, poor skin permeability), requires enhanced topical delivery systems.
Objective
Develop optimized transethosomal gel for superior skin penetration and antifungal efficacy against Candida albicans.
Methods
Cold method preparation, Central Composite Design (CCD) optimization (soy lecithin 2.5–3.5% w/v, ethanol 20–60% v/v; n = 9 formulations). Evaluated vesicle size, entrapment efficiency (EE), zeta potential, Transmission Electron Microscopy (TEM), Fourier Transform Infrared (FTIR) spectroscopy. Carbopol 934 gel incorporation. Assessed In vitro release, ex vivo Franz permeation (cellophane MWCO 12–14 kDa, PBS pH 7.4, 32 °C, 400 rpm; samples: 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 24 h), antifungal disc diffusion, In vivo irritation (Wistar rats, OECD 404), Confocal Laser Scanning Microscopy (CLSM; Rhodamine B λex 540/λem 630 nm) .
Results
Optimized F-3: EE 81.56%, vesicle size 360.15 nm (Table 3). Transethosomal gel showed 48.76% permeation vs. plain gel (p < 0.05), inhibition zone 13.50 ± 0.02 mm vs. Micogel® 9.60 mm, dermis penetration via CLSM.
Conclusion
CCD-optimized transethosomal gel enhances miconazole delivery vs. existing formulations, warranting clinical evaluation.
Graphical Abstract
Miconazole nitrate was formulated into transethosomes using the cold method with phospholipids, ethanol, and an edge activator to improve skin permeability. Formulation variables (ethanol and soy lecithin concentration) were optimized via Central Composite Design, with entrapment efficiency and vesicle size evaluated through 3D surface plots, and morphology confirmed by TEM. In vitro testing included antifungal activity against Candida albicans (disc diffusion) and drug permeation studies using a Franz diffusion cell. In vivo skin irritation tests were conducted on Wistar rats, while ex vivo penetration was assessed by CLSM using fluorescently labeled gel. The optimized formulation achieved high entrapment efficiency (~ 81.56%), small vesicle size (~ 360.15 nm), and stability, showing a larger inhibition zone than marketed cream, higher 24-hour cumulative drug release, minimal skin irritation, and confirmed deep skin penetration into the epidermis and dermis.
{"title":"Development and Evaluation of Miconazole Nitrate-Loaded Transethosomal Gel for Enhanced Skin Permeability and Antifungal Efficacy","authors":"Naina Dubey, Seema Sharma, Manish Mohan Ghadage, Sampat Singh Tanwar","doi":"10.1007/s12247-025-10354-4","DOIUrl":"10.1007/s12247-025-10354-4","url":null,"abstract":"<div><h3>Background</h3><p>Miconazole nitrate, a BCS Class II drug (< 3 µg/mL solubility, poor skin permeability), requires enhanced topical delivery systems.</p><h3>Objective</h3><p>Develop optimized transethosomal gel for superior skin penetration and antifungal efficacy against <i>Candida albicans</i>.</p><h3>Methods</h3><p>Cold method preparation, Central Composite Design (CCD) optimization (soy lecithin 2.5–3.5% w/v, ethanol 20–60% v/v; <i>n</i> = 9 formulations). Evaluated vesicle size, entrapment efficiency (EE), zeta potential, Transmission Electron Microscopy (TEM), Fourier Transform Infrared (FTIR) spectroscopy. Carbopol 934 gel incorporation. Assessed In vitro release, ex vivo Franz permeation (cellophane MWCO 12–14 kDa, PBS pH 7.4, 32 °C, 400 rpm; samples: 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 24 h), antifungal disc diffusion, In vivo irritation (Wistar rats, OECD 404), Confocal Laser Scanning Microscopy (CLSM; Rhodamine B λex 540/λem 630 nm) .</p><h3>Results</h3><p>Optimized F-3: EE 81.56%, vesicle size 360.15 nm (Table 3). Transethosomal gel showed 48.76% permeation vs. plain gel (<i>p</i> < 0.05), inhibition zone 13.50 ± 0.02 mm vs. Micogel<sup>®</sup> 9.60 mm, dermis penetration via CLSM.</p><h3>Conclusion</h3><p>CCD-optimized transethosomal gel enhances miconazole delivery vs. existing formulations, warranting clinical evaluation.</p><h3>Graphical Abstract</h3><p>Miconazole nitrate was formulated into transethosomes using the cold method with phospholipids, ethanol, and an edge activator to improve skin permeability. Formulation variables (ethanol and <i>soy lecithin</i> concentration) were optimized via Central Composite Design, with entrapment efficiency and vesicle size evaluated through 3D surface plots, and morphology confirmed by TEM. In vitro testing included antifungal activity against <i>Candida albicans</i> (disc diffusion) and drug permeation studies using a Franz diffusion cell. In vivo skin irritation tests were conducted on Wistar rats, while ex vivo penetration was assessed by CLSM using fluorescently labeled gel. The optimized formulation achieved high entrapment efficiency (~ 81.56%), small vesicle size (~ 360.15 nm), and stability, showing a larger inhibition zone than <i>mark</i>eted cream, higher 24-hour cumulative drug release, minimal skin irritation, and confirmed deep skin penetration into the epidermis and dermis.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"21 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145982690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1007/s12247-025-10364-2
Prarthana Radhakrishnan, Dhanabal S.P, Ganesh GNK
Abstract
The United States Food and Drug Administration (USFDA) regulates and inspects pharmaceutical drug products for its current good manufacturing process (cGMP) and data governance. The Food and Drug Administration (FDA) aims to monitor all drug substances intended for marketing within the United States to ensure compliance with its safety, efficacy, purity, and quality standards. An evaluation of Inspection trends and FDA FORM 483 observations for biologics from 2010 to 2025 reveals persistent areas of regulatory concern, evolving inspectional priorities, and significant disruptions due to global events like the COVID-19 pandemic.
Objective
The purpose of the study is to offer impartial insights into regulatory trends and to identify any underlying issues contributing to a site's non-compliance status. The trends in the inspection and issuance of FORM 483 for biologics for the past 15 years were analyzed to understand the probability of resulting enforcement actions. The study also aims to guide the biologic manufacturers and provide preventive measures to overcome possible regulatory violations.
Method
Cross-sectional examination of Inspection data and FORM 483 citations published in public databases by the FDA for inspections under the Biologics, covering the period from January 2010 to August 2025, was selected for the study. All the related metadata was accessed from the FDA Inspection Dashboard and Inspection Observation page on the FDA website. The data was deeply analysed, tabulated and understood the Code of Federal Regulations (CFR) violations and their root cause.
Results
The data collected was thoroughly evaluated, summarized, and the most common violations were identified. From the study, it is evident that the frequent violations are related to cGMP issues, like failure to follow written Standard Operating Procedures (SOP), failure to maintain contemporaneous documentation, and not performing thorough investigation before batch release, corresponding to 34%, 21%, and 14%, respectively.
Conclusion
The trend in the inspections and FORM 483 is mainly on cGMP Violations. A complete understanding of the FDA inspection and the requirements for good biologic manufacturing process is a must. Following proper Data governance principles and maintaining an internal audit checklist, training of employees on both evolving technology and guidelines will make an effective change and possibly reduce enforcement actions.
摘要美国食品药品监督管理局(USFDA)对药品的现行良好生产工艺(cGMP)和数据治理进行监管和检查。美国食品和药物管理局(FDA)的目标是监控所有拟在美国销售的原料药,以确保其符合其安全性、有效性、纯度和质量标准。对2010年至2025年生物制品的检查趋势和FDA FORM 483观察结果的评估揭示了监管关注的持续领域,不断变化的检查优先级以及由于COVID-19大流行等全球事件造成的重大中断。目的本研究的目的是对监管趋势提供公正的见解,并确定导致站点不合规状态的任何潜在问题。分析了过去15年生物制剂483表格的检查和签发趋势,以了解由此产生的执法行动的可能性。该研究还旨在指导生物制剂制造商,并提供预防措施,以克服可能的法规违规行为。方法选择2010年1月至2025年8月期间FDA在公共数据库中公布的关于生物制剂检查的检查数据和FORM 483引用进行横断面检查。所有相关的元数据都是从FDA网站上的FDA Inspection Dashboard和Inspection Observation页面访问的。这些数据经过了深入分析和制表,并了解了违反联邦法规(CFR)的行为及其根本原因。结果对收集到的数据进行了全面的评估和总结,并确定了最常见的违规行为。从研究中可以明显看出,频繁的违规行为与cGMP问题有关,如未遵循书面的标准操作程序(SOP),未保存同期文件,以及在批放行前未进行彻底调查,分别对应34%,21%和14%。结论检查和FORM 483的趋势主要集中在违反cGMP方面。必须完全了解FDA检查和良好生物生产工艺的要求。遵循适当的数据治理原则和维护内部审计清单,培训员工了解不断发展的技术和指导方针,将有效地改变并可能减少执法行动。
{"title":"Comprehensive Analysis of FDA Form 483 Issued for Biologics from 2010 to 2025: Identifying Trends and Areas of Concern","authors":"Prarthana Radhakrishnan, Dhanabal S.P, Ganesh GNK","doi":"10.1007/s12247-025-10364-2","DOIUrl":"10.1007/s12247-025-10364-2","url":null,"abstract":"<div><h3>Abstract</h3><p>The United States Food and Drug Administration (USFDA) regulates and inspects pharmaceutical drug products for its current good manufacturing process (cGMP) and data governance. The Food and Drug Administration (FDA) aims to monitor all drug substances intended for marketing within the United States to ensure compliance with its safety, efficacy, purity, and quality standards. An evaluation of Inspection trends and FDA FORM 483 observations for biologics from 2010 to 2025 reveals persistent areas of regulatory concern, evolving inspectional priorities, and significant disruptions due to global events like the COVID-19 pandemic.</p><h3>Objective</h3><p>The purpose of the study is to offer impartial insights into regulatory trends and to identify any underlying issues contributing to a site's non-compliance status. The trends in the inspection and issuance of FORM 483 for biologics for the past 15 years were analyzed to understand the probability of resulting enforcement actions. The study also aims to guide the biologic manufacturers and provide preventive measures to overcome possible regulatory violations.</p><h3>Method</h3><p>Cross-sectional examination of Inspection data and FORM 483 citations published in public databases by the FDA for inspections under the Biologics, covering the period from January 2010 to August 2025, was selected for the study. All the related metadata was accessed from the FDA Inspection Dashboard and Inspection Observation page on the FDA website. The data was deeply analysed, tabulated and understood the Code of Federal Regulations (CFR) violations and their root cause.</p><h3>Results</h3><p>The data collected was thoroughly evaluated, summarized, and the most common violations were identified. From the study, it is evident that the frequent violations are related to cGMP issues, like failure to follow written Standard Operating Procedures (SOP), failure to maintain contemporaneous documentation, and not performing thorough investigation before batch release, corresponding to 34%, 21%, and 14%, respectively.</p><h3>Conclusion</h3><p>The trend in the inspections and FORM 483 is mainly on cGMP Violations. A complete understanding of the FDA inspection and the requirements for good biologic manufacturing process is a must. Following proper Data governance principles and maintaining an internal audit checklist, training of employees on both evolving technology and guidelines will make an effective change and possibly reduce enforcement actions. </p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"21 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145982936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1007/s12247-025-10339-3
Rasha Mohamed, Mohammed Hussein, El Sayed El Tamany, Nasser Mostafa, Ahmed Abbas
Background
Obesity, characterized by lipid accumulation, oxidative stress, and inflammation, remains a major public health challenge. This study aimed to investigate the therapeutic efficacy of diosgenin-loaded silver nanoparticles (Dio-AgNPs) in modulating obesity-induced metabolic and molecular dysfunction through integrated biochemical, gene expression, and molecular docking approaches.
Methods
Male albino rats were randomly assigned to control and experimental groups, with Dio-AgNPs administered at two distinct doses. Dio-AgNPs were synthesized and characterized using UV-Vis spectroscopy, TEM, DLS, and zeta potential measurements to confirm particle size and stability. Biochemical analyses included serum lipid profile (triglycerides, total cholesterol, LDL-c, HDL-c), fasting glucose, insulin levels, and HOMA-IR for insulin sensitivity. Oxidative stress markers (MDA) and antioxidant enzymes (SOD, CAT, GPx) were measured spectrophotometrically. Inflammatory cytokines (TNF-α and IL-6) were quantified by ELISA. Gene expression of lipogenic enzymes (ACC and FAS) and antioxidant-related genes was assessed using quantitative real-time PCR (qRT-PCR). Molecular docking simulations were performed to evaluate diosgenin’s binding affinities and interactions with ACC and FAS enzyme active sites.
Results
Dio-AgNP-treated rats showed significant reductions in serum triglycerides, total cholesterol, LDL-c, and fasting glucose compared to controls, while HDL-c and insulin sensitivity were markedly improved. Antioxidant enzyme activities (SOD, CAT, GPx) increased significantly, and MDA levels decreased, indicating oxidative stress attenuation. ELISA confirmed reduced levels of TNF-α and IL-6, revealing anti-inflammatory effects. Gene expression analysis demonstrated dose-dependent downregulation of ACC and FAS, along with upregulation of antioxidant and insulin-responsive genes. Molecular docking results revealed strong binding interactions of diosgenin with both ACC and FAS enzymes, supporting enzymatic inhibition and the transcriptional trends observed. Silver nanoparticle delivery enhanced bioavailability and target specificity.
Conclusion
This is the first report, to our knowledge, that combines biochemical, gene expression, and molecular docking data to investigate Dio-AgNPs’ anti-obesity effects. The findings highlight a promising nanomedicine-based approach for metabolic regulation and pave the way for further research in therapeutic nanoparticle design and application.
{"title":"Diosgenin-Loaded Silver Nanoparticles Mitigate Obesity-Related Metabolic Dysfunction: an Integrative Analysis of Biochemical, Transcriptional, and Molecular Docking Evidence","authors":"Rasha Mohamed, Mohammed Hussein, El Sayed El Tamany, Nasser Mostafa, Ahmed Abbas","doi":"10.1007/s12247-025-10339-3","DOIUrl":"10.1007/s12247-025-10339-3","url":null,"abstract":"<div><h3>Background</h3><p>Obesity, characterized by lipid accumulation, oxidative stress, and inflammation, remains a major public health challenge. This study aimed to investigate the therapeutic efficacy of diosgenin-loaded silver nanoparticles (Dio-AgNPs) in modulating obesity-induced metabolic and molecular dysfunction through integrated biochemical, gene expression, and molecular docking approaches.</p><h3>Methods</h3><p>Male albino rats were randomly assigned to control and experimental groups, with Dio-AgNPs administered at two distinct doses. Dio-AgNPs were synthesized and characterized using UV-Vis spectroscopy, TEM, DLS, and zeta potential measurements to confirm particle size and stability. Biochemical analyses included serum lipid profile (triglycerides, total cholesterol, LDL-c, HDL-c), fasting glucose, insulin levels, and HOMA-IR for insulin sensitivity. Oxidative stress markers (MDA) and antioxidant enzymes (SOD, CAT, GPx) were measured spectrophotometrically. Inflammatory cytokines (TNF-α and IL-6) were quantified by ELISA. Gene expression of lipogenic enzymes (<i>ACC</i> and <i>FAS</i>) and antioxidant-related genes was assessed using quantitative real-time PCR (qRT-PCR). Molecular docking simulations were performed to evaluate diosgenin’s binding affinities and interactions with ACC and FAS enzyme active sites.</p><h3>Results</h3><p>Dio-AgNP-treated rats showed significant reductions in serum triglycerides, total cholesterol, LDL-c, and fasting glucose compared to controls, while HDL-c and insulin sensitivity were markedly improved. Antioxidant enzyme activities (SOD, CAT, GPx) increased significantly, and MDA levels decreased, indicating oxidative stress attenuation. ELISA confirmed reduced levels of TNF-α and IL-6, revealing anti-inflammatory effects. Gene expression analysis demonstrated dose-dependent downregulation of <i>ACC</i> and <i>FAS</i>, along with upregulation of antioxidant and insulin-responsive genes. Molecular docking results revealed strong binding interactions of diosgenin with both ACC and FAS enzymes, supporting enzymatic inhibition and the transcriptional trends observed. Silver nanoparticle delivery enhanced bioavailability and target specificity.</p><h3>Conclusion</h3><p>This is the first report, to our knowledge, that combines biochemical, gene expression, and molecular docking data to investigate Dio-AgNPs’ anti-obesity effects. The findings highlight a promising nanomedicine-based approach for metabolic regulation and pave the way for further research in therapeutic nanoparticle design and application.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"21 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145982938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ciprofloxacin HCl orodispersible tablets (ODT) were prepared by direct compression of a mixture of superdisintegrants, fillers, and flow enhancers after proper pre-compression analysis. Post-compression analysis was conducted for content uniformity and disintegration time-based screening of the formulation (disintegration time < 30 s). In vitro (IP type I) and ex-situ (buccal mucosa) analyses were performed in simulated mucosal (pH 7.4) and salivary (pH 6.4) phosphate buffers. Statistical analysis included two-way ANOVA, Pearson’s correlation coefficient (KPC), Student’s t-test, and Bootstrap f2. Pre-compression analysis indicated that flow properties were highly affected by superdisintegrant polymers, in the order of crosspovidone > sodium starch glycolate > croscarmellose sodium, along with talc and magnesium stearate. A similar trend was observed for disintegration time, with formulation F4 showing the shortest disintegration time, followed by F3. In vitro studies revealed that the formulation follows a Makoid-Banakar drug release model, with an initial burst release of 15% in the first 5 min at pH levels of 6.4 and 7.4. In contrast, the Peppas-Sahlin kinetic model fits the release profile in water. Ex-situ permeation studies revealed that F4 exhibited higher permeability and flux than F3 at both pH levels of 6.4 and 7.4, with an approximately 1.3-fold increase. This improvement is likely due to the higher presence of wetting-based superdisintegrants in F4.
Graphical Abstract
In vitro analysis of orodispersible tablets of Ciprofloxacin HCl
{"title":"Development and in Vitro Characterization of the Ciprofloxacin Hydrochloride Orodispersible Tablets for Treating Oral Plaque","authors":"Ishu Garg, Aditi Sayana, Urmi Chaurasia, Ashish Uniyal, Shivani Rawat, Madhu Verma, Iti Chauhan","doi":"10.1007/s12247-025-10366-0","DOIUrl":"10.1007/s12247-025-10366-0","url":null,"abstract":"<div><p>Ciprofloxacin HCl orodispersible tablets (ODT) were prepared by direct compression of a mixture of superdisintegrants, fillers, and flow enhancers after proper pre-compression analysis. Post-compression analysis was conducted for content uniformity and disintegration time-based screening of the formulation (disintegration time < 30 s). In vitro (IP type I) and <i>ex-situ</i> (buccal mucosa) analyses were performed in simulated mucosal (pH 7.4) and salivary (pH 6.4) phosphate buffers. Statistical analysis included two-way ANOVA, Pearson’s correlation coefficient (KPC), Student’s t-test, and Bootstrap f2. Pre-compression analysis indicated that flow properties were highly affected by superdisintegrant polymers, in the order of crosspovidone > sodium starch glycolate > croscarmellose sodium, along with talc and magnesium stearate. A similar trend was observed for disintegration time, with formulation F4 showing the shortest disintegration time, followed by F3. In vitro studies revealed that the formulation follows a Makoid-Banakar drug release model, with an initial burst release of 15% in the first 5 min at pH levels of 6.4 and 7.4. In contrast, the Peppas-Sahlin kinetic model fits the release profile in water. <i>Ex-situ</i> permeation studies revealed that F4 exhibited higher permeability and flux than F3 at both pH levels of 6.4 and 7.4, with an approximately 1.3-fold increase. This improvement is likely due to the higher presence of wetting-based superdisintegrants in F4.</p><h3>Graphical Abstract</h3><p><i>In vitro </i>analysis of orodispersible tablets of Ciprofloxacin HCl</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"21 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145982761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}